1-8 of 8
Patricia M. LoRusso
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Precision Medicine: Progress, Pitfalls, and Promises

Patrick G. Pilié, Patricia M. LoRusso, Timothy A. Yap
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (12): 2641–2644.
https://doi.org/10.1158/1535-7163.MCT-17-0904
Published: 03 December 2017
View article titled, Precision Medicine: Progress, Pitfalls, and Promises
Open the PDF for Precision Medicine: Progress, Pitfalls, and Promises in another window
Journal Articles

Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study

Jason M. Summa, Daniel D. Von Hoff, Jasgit C. Sachdev, Monica M. Mita, Patricia M. LoRusso, Peter D. Eisenberg, Howard A. Burris, Lowell L. Hart, Hagop Youssoufian, Donald M. Parsons, Susan C. Low
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B144.
https://doi.org/10.1158/1535-7163.TARG-15-B144
Published: 01 December 2015
View article titled, Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study
Journal Articles

Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC)

Geoffrey I. Shapiro, Afshin Dowlati, Patricia M. LoRusso, Joseph P. Eder, Adrienne Anderson, Khanh T. Do, Michael H. Kagey, Cynthia Sirard, James E. Bradner, Steven B. Landau
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A49.
https://doi.org/10.1158/1535-7163.TARG-15-A49
Published: 01 December 2015
View article titled, Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC)
Journal Articles

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team

Patricia M. LoRusso, Scott A. Boerner, Mary Jo Pilat, Karen M. Forman, Clarice Y. Zuccaro, Jeffrey A. Kiefer, Winnie S. Liang, Sally Hunsberger, Bruce G. Redman, Svetomir N. Markovic, Aleksandar Sekulic, Alan H. Bryce, Richard W. Joseph, C. Lance Cowey, Leslie Anne Fecher, Jeffrey Alan Sosman, Paul B. Chapman, Gary K. Schwartz, David W. Craig, John D. Carpten, Jeffrey M. Trent
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (8): 1962–1971.
https://doi.org/10.1158/1535-7163.MCT-15-0153
Published: 05 August 2015
View article titled, Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team
Open the PDF for Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team in another window
Journal Articles

Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study.

Joaquin Mateo, Patrick Schoffski, David Olmos, Herlinde Dumez, Victor Moreno, Fei Jie, Srinivasu Poondru, Nancy L. Samberg, Jan M. Van Tornout, Stanley B. Kaye, Patricia M. LoRusso
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B187.
https://doi.org/10.1158/1535-7163.TARG-13-B187
Published: 01 November 2013
View article titled, Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study.
Journal Articles

Abstract B188: Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors.

Patricia M. LoRusso, Sarina A. Piha-Paul, Alexander D. Colevas, Vikram Malhi, Dawn Colburn, Ming Yin, Jennifer A. Low, Richard A. Graham
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B188.
https://doi.org/10.1158/1535-7163.TARG-11-B188
Published: 12 November 2011
View article titled, Abstract B188: Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors.
Journal Articles

Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors

Neil Faulkner, Patricia M. LoRusso, Tina Guthrie, Jean‐Charles Soria, Ratislav Bahleda, Johanna C. Bendell, Jeffrey R. Infante, Christophe Massard, Barbara Van Leeuwen, Jean‐Francois Martini, Christian Scheffold, Howard A. Burris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C197.
https://doi.org/10.1158/1535-7163.TARG-09-C197
Published: 10 December 2009
View article titled, Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors
Journal Articles

Abstract B61: Multicenter phase I clinical trial of an insulin like growth factor (IGF‐R) inhibitor (IMC‐A12) in combination with a mammalian target of rapamycin (mTOR) inhibitor (CCI‐779) to overcome resistance to mTOR inhibition

Aung Naing, Razelle Kurzrock, Helen Chen, David S. Hong, Gerald Falchook, Laurence Doyle, Kristie Iawhorn, Angelika M. Burger, Chann Ng, Hesham Amin, Patricia M. LoRusso
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B61.
https://doi.org/10.1158/1535-7163.TARG-09-B61
Published: 10 December 2009
View article titled, Abstract B61: Multicenter phase I clinical trial of an insulin like growth factor (IGF‐R) inhibitor (IMC‐A12) in combination with a mammalian target of rapamycin (mTOR) inhibitor (CCI‐779) to overcome resistance to mTOR inhibition